0955 GMT - A U.S. investigation into pharmaceutical imports and potential tariffs in the coming months will likely limit clarity from pharma companies during their 1Q results, Barclays analysts say in a note. The investigation, initiated April 1, aims to assess the national security implications of pharmaceutical imports, including finished generics, nongenerics and active pharmaceutical ingredients, and has to be finalized in around nine months. "With Pharma having been excluded from the initial reciprocal tariffs and it being our house view that some sort of Commerce Department investigation being required for these sectoral tariffs, this isn't too surprising but at least provides some timing framing," they say. Barclays analysts estimate that AstraZeneca, Roche and Grifols appear most insulated, whereas GSK and Sandoz look most exposed to a potential tariff risk. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
April 15, 2025 05:55 ET (09:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。